BCTX - BriaCell Therapeutics Corp. Stock Price, Fair Value and News

$12.59+2.59 (+25.90%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

BCTX Price Action

Last 7 days

22.4%

Last 30 days

25.9%

Last 90 days

63.1%

Trailing 12 Months

8.5%

BCTX RSI Chart

BCTX Valuation

Market Cap

23.7M

Price/Earnings (Trailing)

-0.9

Price/Sales (Trailing)

7.4K

Price/Free Cashflow

-0.84

BCTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

BCTX Fundamentals

BCTX Revenue

Revenue (TTM)

3.1K

BCTX Earnings

Earnings (TTM)

-26.3M

Earnings Growth (Yr)

-566.41%

Earnings Growth (Qtr)

-32.06%

BCTX Profitability

Return on Equity

-151.79%

Return on Assets

-121.53%

Free Cashflow Yield

-118.77%

BCTX Investor Care

Shares Dilution (1Y)

248.16%

Diluted EPS (TTM)

-65.04

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2022	0	0	0	0
2021	0	0	3.1K	0
2020	0	0	0	0
2019	0	0	12.0K	0
2018	0	0	16.0K	0

Get all data in R, Python etc through our Historical Stock Data APIs

About BriaCell Therapeutics Corp.

BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test that determines the patients' HLA types. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to conduct preclinical studies to develop and test Bria-OTS cellular immunotherapy as a treatment for cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.

CEO	Dr. William V. Williams M.D.
WEBSITE	briacell.com
SECTOR	Healthcare
INDUSTRY	Biotechnology

BriaCell Therapeutics Corp. Frequently Asked Questions

What is the ticker symbol for BriaCell Therapeutics Corp.? What does BCTX stand for in stocks?

BCTX is the stock ticker symbol of BriaCell Therapeutics Corp.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of BriaCell Therapeutics Corp. (BCTX)?

As of Wed Dec 03 2025, market cap of BriaCell Therapeutics Corp. is 23.72 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BCTX stock?

You can check BCTX's fair value in chart for subscribers.

Is BriaCell Therapeutics Corp. a good stock to buy?

The fair value guage provides a quick view whether BCTX is over valued or under valued. Whether BriaCell Therapeutics Corp. is cheap or expensive depends on the assumptions which impact BriaCell Therapeutics Corp.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BCTX.

What is BriaCell Therapeutics Corp.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, BCTX's PE ratio (Price to Earnings) is -0.9 and Price to Sales (PS) ratio is 7.37 Thousand. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BCTX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on BriaCell Therapeutics Corp.'s stock?

In the past 10 years, BriaCell Therapeutics Corp. has provided -0.309 (multiply by 100 for percentage) rate of return.